Skip to main content

Advertisement

Table 2 Genotype distribution of the FAS and FASL polymorphisms among patients with index OPC and non-OPC and their associations with risk of SPM

From: Site disparities in apoptotic variants as predictors of risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck

Variables OPC (N = 42) Non-OPC (N = 82) cHRsa (95 % CI), P Adj. HRs (95 % CI) b, P
  SPM (N) % SPM (N) % OPC Non-OPC OPC Non-OPC
FAS 670 A > G         
 AA (ref.) 7 16.7 13 15.9 1.0 1.0 1.0 1.0
 AG + GG 35 83.3 69 84.1 1.9 (0.8–4.9), 0.121 2.2 (1.2–5.7), 0.048 2.2 (0.9–5.3), 0.051 2.4 (1.1–5.1), 0.043
FAS 1377 G > A         
 GG (ref.) 34 80.9 64 78.0 1.0 1.0 1.0 1.0
 AG + AA 8 19.1 18 22.0 0.7 (0.3–2.1), 0.435 1.1 (0.4–1.6), 0.378 0.8 (0.4–1.9), 0.476 1.0 (0.5–1.8), 0.622
FASL124 A > G         
 AA (ref.) 31 73.8 63 76.8 1.0 1.0 1.0 1.0
 AG + GG 11 26.2 19 23.2 1.0 (0.4–2.7), 0.489 1.4 (0.7–2.8), 0.567 1.1 (0.5–2.4), 0.587 1.6 (0.9–3.0), 0.124
FASL844 C > T         
 CC (ref.) 11 26.2 26 31.7 1.0 1.0 1.0 1.0
 CT + TT 31 73.8 56 68.3 2.5 (1.1–5.8), 0.043 1.8 (1.1–3.2), 0.041 2.7 (1.2–6.0), 0.032 1.7 (1.0–3.0), 0.049
  1. ref.: reference group
  2. aCrude HRs
  3. bHRs were adjusted for age, sex, ethnicity, smoking, alcohol, index cancer stage, and treatment